Figure 2From: Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancerKaplan-Meier plots of invasive disease-free survival depending on the UGT2B7His268Tyr genotype in epirubicin-treated patients. (b) epirubicin-treated patients subsequently treated with tamoxifen.Back to article page